Mara Goldstein Steps to the Sidelines on Ignyta Inc (RXDX) But Boosts Price Target Following Billion-Dollar Acquisition by Roche

Cantor’s Mara Goldstein believes the valuation of the $1.7 billion takeover by Roche is sound, and does not think another bid for RXDX is forthcoming.

Ignyta Inc (RXDX) Merger with Biotech Giant Roche “Makes Sense” to This Bull Who Spotlights a Robust Strength in Oncology

Cantor’s Mara Goldstein notes that RXDX’s next transaction could be ALK, calling the deal with Roche quite a “gift” for shareholders.

Ignyta Inc (RXDX) Could Make You Big Time Money

I have written a lot of articles over the years concerning my biotech investments and thankfully have done pretty well anticipating good entry …